

# REGENERON PHARMACEUTICALS INC.

ISIN: US75886F1075 WKN: 75886F107 Asset Class: Stock

**Company** 2022/05/27 20:34:12

**Price**  
**688.88**  
USD

**Difference**  0.80%(5.44)

**REGENERON**



**Contact Details**

REGENERON PHARMACEUTICALS INC.  
--  
777 Old Saw Mill River Road  
10591-6707 Tarrytown

Tel: 1-914-847-7000  
Fax: -  
Web: <http://www.regeneron.com>  
E-mail: -

## Company Profile

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as Velocimmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

## Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2021		2020		2019	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
<b>Current assets</b>	14,014,900,000		9,779,100,000		7,689,100,000	
<b>Common stock capital</b>		100,000		100,000		100,000
<b>Fixed assets</b>	11,419,900,000		7,384,200,000		7,116,100,000	
<b>Equity capital of a company</b>		18,768,800,000		11,025,300,000		11,089,700,000
<b>Cash and cash equivalents</b>	2,885,600,000		2,193,700,000		1,617,800,000	
<b>Accrued liabilities</b>		0		0		0
<b>Other assets</b>	-		-		-	
<b>Current liabilities</b>		3,932,500,000		2,697,400,000		2,096,600,000
<b>Prepayments and accrued income</b>	-		-		-	
<b>Non-current liabilities</b>		2,733,500,000		3,440,600,000		1,618,900,000
<b>Different income</b>		-		-		-
<b>Other liabilities</b>		753,500,000		744,900,000		905,000,000
<b>Total assets</b>	25,434,800,000	25,434,800,000	17,163,300,000	17,163,300,000	14,805,200,000	14,805,200,000

## Balance notes

	2021	2020	2019
<b>Accounting standard</b>	US-GAAP	US-GAAP	US-GAAP
<b>Employees</b>	10,368	9,123	8,100
<b>Equity ratio</b>	73.79%	64.24%	74.90%
<b>Debt-equity ratio</b>	35.52%	55.67%	33.50%

## Others

	2021	2020	2019
<b>Tax Expense Rate</b>	13.41%	7.80%	12.90%

# REGENERON PHARMACEUTICALS INC.

ISIN: US75886F1075 WKN: 75886F107 Asset Class: Stock

## Income statement

	2021	2020	2019
<b>Turnover</b>	16,071,700,000	8,497,100,000	7,863,400,000
<b>Net income</b>	8,075,300,000	3,513,200,000	2,115,800,000
<b>EBIT</b>	8,742,234,270	3,603,163,410	2,291,329,810
<b>Operating income before taxes</b>	9,325,800,000	3,810,400,000	2,429,100,000
<b>Cash Flow</b>	7,081,300,000	2,618,100,000	2,430,000,000
<b>Net interest income</b>	-57,300,000	-56,900,000	-30,200,000
<b>Research and development expenses</b>	2,621,900,000	2,499,100,000	2,826,300,000
<b>Income taxes</b>	1,250,500,000	297,200,000	313,300,000
<b>Result from investments in subsidiaries, associates and other</b>	-	-	-
<b>Revenues per employee</b>	1,444,252	867,779	904,485

## Board of Directors

## Members of Management Board

P. Vagelos	Chairman of Board of Directors
Bonnie Bassler	Member of Board of Directors
George Yancopoulos	Member of Board of Directors
Huda Zoghbi	Member of Board of Directors
Joseph Goldstein	Member of Board of Directors
Marc Tessier-Lavigne	Member of Board of Directors
Michael Brown	Member of Board of Directors
N. Coles	Member of Board of Directors
Arthur Ryan	Member of Board of Directors
Christine Poon	Member of Board of Directors
George Sing	Member of Board of Directors
Leonard S. Schleifer	Chairman of Managing Board
George D. Yancopoulos	Member of Executive Committee
Robert E. Landry	Member of Executive Committee